

REFERENCES

1. Paredes, R., Clotet B., "Clinical management of HIV-1 resistance," *Antiviral Res*, 2010; 85: 245-65.
2. Barouch, D.H., "Challenges in the development of an HIV-1 vaccine," *Nature*, 2008; 455: 613-9.
3. Girard, M.P., Plotkin S.A., "HIV vaccine development at the turn of the 21st century," *Curr Opin HIV AIDS*, 2012; 7: 4-9.
4. Stumpp, M.T., Binz H.K., Amstutz P., "DARPin: a new generation of protein therapeutics," *Drug Discov Today*, 2008; 13: 695-701.
5. Schweizer, A., Rusert P., Berlinger L., Ruprecht C.R., Mann A., Cortesy S., *et al.*, "CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics," *PLoS Pathog*, 2008; 4: e1000109.
6. Pugach, P., Krarup A., Gettie A., Kuroda M., Blanchard J., Piatak M., Jr., *et al.*, "In vivo binding and retention of CD4-specific DARPin 57.2 in macaques," *PLoS One*, 2010; 5: e12455.
7. Geijtenbeek, T.B., Kwon D.S., Torensma R., van Vliet S.J., van Duijnhoven G.C., Middel J., *et al.*, "DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells," *Cell*, 2000; 100: 587-97.
8. Wilen, C.B., Tilton J.C., Doms R.W., "HIV: cell binding and entry," *Cold Spring Harbor perspectives in medicine*, 2012; 2: a006866.
9. Chan, D.C., Fass D., Berger J.M., Kim P.S., "Core structure of gp41 from the HIV envelope glycoprotein," *Cell*, 1997; 89: 263-73.
10. Harrison, S., Wang J., Yan Y., Garrett T., Liu J., Moebius U., *et al.* "Structure and interactions of CD4." in *Cold Spring Harbor symposia on quantitative biology*. 1992. Cold Spring Harbor Laboratory Press.
11. Brady, R., Dodson E., Dodson G., Lange G., Davis S., Williams A., *et al.*, "Crystal structure of domains 3 and 4 of rat CD4: relation to the NH2-terminal domains," *Science*, 1993; 260: 979-83.

12. Leahy, D., "A structural view of CD4 and CD8," *The FASEB journal*, 1995; 9: 17-25.
13. Checkley, M.A., Luttge B.G., Freed E.O., "HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation," *J Mol Biol*, 2011; 410: 582-608.
14. Kwong, P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A., "Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody," *Nature*, 1998; 393: 648-59.
15. Pancera, M., Majeed S., Ban Y.E., Chen L., Huang C.C., Kong L., *et al.*, "Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility," *Proc Natl Acad Sci U S A*, 2010; 107: 1166-71.
16. Liu, J., Bartesaghi A., Borgnia M.J., Sapiro G., Subramaniam S., "Molecular architecture of native HIV-1 gp120 trimers," *Nature*, 2008; 455: 109-13.
17. Ryu, S.-E., Kwong P.D., Truneh A., Porter T.G., Arthos J., Rosenberg M., *et al.*, "Crystal structure of an HIV-binding recombinant fragment of human CD 4," *Nature*, 1990; 348: 419-26.
18. Vermeire, K., Schols D., "Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor," *Expert Opin Investig Drugs*, 2005; 14: 1199-212.
19. Allaway, G.P., Davis-Bruno K.L., Beaudry G.A., Garcia E.B., Wong E.L., Ryder A.M., *et al.*, "Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates," *AIDS Res Hum Retroviruses*, 1995; 11: 533-9.
20. Gauduin, M.C., Allaway G.P., Olson W.C., Weir R., Maddon P.J., Koup R.A., "CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates," *J Virol*, 1998; 72: 3475-8.
21. Wilen, C.B., Tilton J.C., Doms R.W., *Molecular mechanisms of HIV entry*, in *Viral Molecular Machines*. Springer 2012, 223-42, 1461409799
22. Jacobson, J.M., Israel R.J., Lowy I., Ostrow N.A., Vassilatos L.S., Barish M., *et al.*, "Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542," *Antimicrob Agents Chemother*, 2004; 48: 423-9.

23. Cooley, L.A., Lewin S.R., "HIV-1 cell entry and advances in viral entry inhibitor therapy," *J Clin Virol*, 2003; 26: 121-32.
24. Tamaskovic, R., Simon M., Stefan N., Schwill M., Plückthun A., "Designed ankyrin repeat proteins (DARPs) from research to therapy," *Methods Enzymol*, 2012; 503: 101-34.
25. Li, J., Mahajan A., Tsai M.D., "Ankyrin repeat: a unique motif mediating protein-protein interactions," *Biochemistry*, 2006; 45: 15168-78.
26. Sedgwick, S.G., Smerdon S.J., "The ankyrin repeat: a diversity of interactions on a common structural framework," *Trends Biochem Sci*, 1999; 24: 311-6.
27. Binz, H.K., Stumpp M.T., Forrer P., Amstutz P., Plückthun A., "Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins," *J Mol Biol*, 2003; 332: 489-503.
28. Ritchie, D.W., "Recent progress and future directions in protein-protein docking," *Curr Protein Pept Sci*, 2008; 9: 1-15.
29. Smith, G.R., Sternberg M.J., "Prediction of protein-protein interactions by docking methods," *Curr Opin Struct Biol*, 2002; 12: 28-35.
30. Halperin, I., Ma B., Wolfson H., Nussinov R., "Principles of docking: An overview of search algorithms and a guide to scoring functions," *Proteins*, 2002; 47: 409-43.
31. Yuriev, E., Ramsland P.A., "Latest developments in molecular docking: 2010-2011 in review," *J Mol Recognit*, 2013; 26: 215-39.
32. Krieger, E., Nabuurs S.B., Vriend G., "Homology modeling," *Methods Biochem Anal*, 2003; 44: 509-23.
33. Nimmanpipug, P., Khampa C., Lee V.S., Nangola S., Tayapiwatana C., "Identification of amino acid residues of a designed ankyrin repeat protein potentially involved in intermolecular interactions with CD4: analysis by molecular dynamics simulations," *J Mol Graph Model*, 2011; 31: 65-75.
34. Wisitponchai, T., Nimmanpipug P., Lee V.S., Tayapiwatana C., "MATLAB process for validating amino acids on CD4 involving in DARPin binding site from ZDOCK molecular docking database," *Chiang Mai J Sci*, 2013; 40: 232-9.
35. Arnberg, N., "Adenovirus receptors: implications for tropism, treatment and targeting," *Rev Med Virol*, 2009; 19: 165-78.

36. Yeh, P., Perricaudet M., "Advances in adenoviral vectors: from genetic engineering to their biology," *The FASEB Journal*, 1997; 11: 615-23.
37. Dimitrov, D.S., "Virus entry: molecular mechanisms and biomedical applications," *Nat Rev Microbiol*, 2004; 2: 109-22.
38. Graham, F.L., Smiley J., Russell W.C., Nairn R., "Characteristics of a human cell line transformed by DNA from human adenovirus type 5," *J Gen Virol*, 1977; 36: 59-74.
39. Fallaux, F.J., Kranenburg O., Cramer S.J., Houweling A., Van Ormondt H., Hoeben R.C., *et al.*, "Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors," *Hum Gene Ther*, 1996; 7: 215-22.
40. Fallaux, F.J., Bout A., van der Velde I., van den Wollenberg D.J., Hehir K.M., Keegan J., *et al.*, "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses," *Hum Gene Ther*, 1998; 9: 1909-17.
41. Schiedner, G., Hertel S., Kochanek S., "Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production," *Hum Gene Ther*, 2000; 11: 2105-16.
42. He, T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B., "A simplified system for generating recombinant adenoviruses," *Proc Natl Acad Sci U S A*, 1998; 95: 2509-14.
43. Luo, J., Deng Z.-L., Luo X., Tang N., Song W.-X., Chen J., *et al.*, "A protocol for rapid generation of recombinant adenoviruses using the AdEasy system," *Nat Protoc*, 2007; 2: 1236-47.
44. Alba, R., Bosch A., Chillon M., "Gutless adenovirus: last-generation adenovirus for gene therapy," *Gene therapy*, 2005; 12: S18-S27.
45. Amalfitano, A., "Next-generation adenoviral vectors: new and improved," *Gene therapy*, 1999; 6: 1643.
46. Hanahan, D., Gluzman Y., "Rescue of functional replication origins from embedded configurations in a plasmid carrying the adenovirus genome," *Mol Cell Biol*, 1984; 4: 302-9.


47. Luo, J., Deng Z.L., Luo X., Tang N., Song W.X., Chen J., *et al.*, "A protocol for rapid generation of recombinant adenoviruses using the AdEasy system," *Nat Protoc*, 2007; 2: 1236-47.
48. Hsu, K.H., Lonberg-Holm K., Alstein B., Crowell R.L., "A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses," *J Virol*, 1988; 62: 1647-52.
49. Al-Mawsawi, L.Q., Wu N.C., Olson C.A., Shi V.C., Qi H., Zheng X., *et al.*, "High-throughput profiling of point mutations across the HIV-1 genome," *Retrovirology*, 2014; 11: 124-.
50. Jiamsakul, A., Sirivichayakul S., Ditangco R., Wong K.-H., Li P.C., Praparattanapan J., *et al.*, "Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007–2010)–TASER-S," *AIDS research and therapy*, 2015; 3.
51. Hamers, R.L., Sigaloff K.C., Kityo C., Mugenyi P., de Wit T.F.R., "Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa," *Current Opinion in HIV and AIDS*, 2013; 8: 19-26.
52. Bártolo, I., Zakovic S., Martin F., Palladino C., Carvalho P., Camacho R., *et al.*, "HIV-1 Diversity, Transmission Dynamics and Primary Drug Resistance in Angola," *PLoS One*, 2014; 9: e113626.
53. Koigi, P., Ngayo M.O., Khamadi S., Ngugi C., Nyamache A.K., "HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya," *BMC Res Notes*, 2014; 7: 890.
54. Wild, C., Oas T., McDanal C., Bolognesi D., Matthews T., "A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition," *Proc Natl Acad Sci U S A*, 1992; 89: 10537-41.
55. Wild, C., Greenwell T., Matthews T., "A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion," *AIDS Res Hum Retroviruses*, 1993; 9: 1051-3.
56. Baba, M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., *et al.*, "A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity," *Proc Natl Acad Sci U S A*, 1999; 96: 5698-703.

57. Tilton, J.C., Amrine-Madsen H., Miamidian J.L., Kitrinou K.M., Pfaff J., Demarest J.F., *et al.*, "HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry," *AIDS Res Hum Retroviruses*, 2010; 26: 13-24.
58. Tilton, J.C., Doms R.W., "Entry inhibitors in the treatment of HIV-1 infection," *Antiviral Res*, 2010; 85: 91-100.
59. Yu, H., Kohl A., Binz H.K., Pluckthun A., Grutter M.G., van Gunsteren W.F., "Molecular dynamics study of the stabilities of consensus designed ankyrin repeat proteins," *Proteins*, 2006; 65: 285-95.
60. Interlandi, G., Wetzel S.K., Settanni G., Pluckthun A., Caflisch A., "Characterization and further stabilization of designed ankyrin repeat proteins by combining molecular dynamics simulations and experiments," *J Mol Biol*, 2008; 375: 837-54.
61. Kramer, M.A., Wetzel S.K., Pluckthun A., Mittl P.R., Grutter M.G., "Structural determinants for improved stability of designed ankyrin repeat proteins with a redesigned C-capping module," *J Mol Biol*, 2010; 404: 381-91.
62. Veisler, D., Dreier B., Blangy S., Lichiere J., Tremblay D., Moineau S., *et al.*, "Crystal structure and function of a DARPIn neutralizing inhibitor of lactococcal phage TP901-1: comparison of DARPIn and camelid VHH binding mode," *J Biol Chem*, 2009; 284: 30718-26.
63. Kummer, L., Parizek P., Rube P., Millgramm B., Prinz A., Mittl P.R., *et al.*, "Structural and functional analysis of phosphorylation-specific binders of the kinase ERK from designed ankyrin repeat protein libraries," *Proc Natl Acad Sci U S A*, 2012; 109: E2248-57.
64. Matthews, B.W., "Hydrophobic interactions in proteins," *eLS*, 2001;
65. Wang, J.H., Meijers R., Xiong Y., Liu J.H., Sakihama T., Zhang R., *et al.*, "Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule," *Proc Natl Acad Sci U S A*, 2001; 98: 10799-804.
66. Rein, D.T., Breidenbach M., Wu H., Han T., Haviv Y.S., Wang M., *et al.*, "Gene transfer to cervical cancer with fiber-modified adenoviruses," *Int J Cancer*, 2004; 111: 698-704.

67. Carson, S.D., Kim K.S., Pirruccello S.J., Tracy S., Chapman N.M., "Endogenous low-level expression of the coxsackievirus and adenovirus receptor enables coxsackievirus B3 infection of RD cells," J Gen Virol, 2007; 88: 3031-8.
68. Pierce, B., Weng Z., "A combination of rescoring and refinement significantly improves protein docking performance," Proteins, 2008; 72: 270-9.
69. Epa, V.C., Dolezal O., Doughty L., Xiao X., Jost C., Pluckthun A., *et al.*, "Structural model for the interaction of a designed Ankyrin Repeat Protein with the human epidermal growth factor receptor 2," PLoS One, 2013; 8: e59163.
70. Nangola, S., Urvoas A., Valerio-Lepiniec M., Khamaikawin W., Sakkhachornphop S., Hong S.-S., *et al.*, "Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein," Retrovirology, 2012; 9: 17.
71. Praditwongwan, W., Chuankhayan P., Saoin S., Wisitponchai T., Lee V.S., Nangola S., *et al.*, "Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex," J Comput Aided Mol Des, 2014; 28: 869-84.

LIST OF PUBLICATION

1. Suwanpaisroj, S., Nangola S., Kitidee K., Tayapiwatana C. "Investigation of Crucial Amino Acid Residue on CD4 Molecule Involving in the HIV-1 Entry Inhibition of DARPin" Proceedings: International Graduate Research Conference 2013, Chiangmai, Thailand, Dec 20, 2013, pp. 45-54.
2. Thammasit, P., Sangboonruang S., Suwanpaisroj S., Khamaikawin W., Intasai N., Kasinrerak W., *et al.*, "Intracellular Acidosis Promotes Mitochondrial Apoptosis Pathway: Role of EMMPRIN Down-regulation via Specific Single-chain Fv Intrabody," J Cancer, 2015; 6: 276-86.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved